T‐cell response after first dose of BNT162b2 SARS‐CoV‐2 vaccine among healthcare workers with previous infection or cross‐reactive immunity

OBJECTIVES: Antibody response to the first dose of BNT162b2 SARS‐CoV‐2 is greater in COVID‐19‐convalescent than in infection‐naïve individuals. However, there are no data about T‐cell response in individuals with pre‐existing cellular immunity. METHODS: We evaluated T‐cell responses in parallel with...

Descripción completa

Detalles Bibliográficos
Autores principales: Casado, Jose L, Haemmerle, Johannes, Vizcarra, Pilar, Rodriguez‐Dominguez, Mario, Velasco, Tamara, Velasco, Hector, Centenera, Elena, Romero‐Hernandez, Beatriz, Fernandez‐Escribano, Marina, Vallejo, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426108/
https://www.ncbi.nlm.nih.gov/pubmed/34522381
http://dx.doi.org/10.1002/cti2.1341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426108/
https://www.ncbi.nlm.nih.gov/pubmed/34522381
http://dx.doi.org/10.1002/cti2.1341

Ejemplares similares